|
The pharma companies are juggling multiple priorities like improving R&D, establishing a presence in global markets, and investing in digital transformation initiatives to move beyond the pill, find new revenue streams, and handle changing customer’s expectations for personalization. Pandemic further complicated the issues with delayed product launches, reduced in-person sales visit potential, supply chain disruption, and delays in drug commercialization. So how are the pharma industry players dealing with this perfect storm? What’s the road to relevant, profitable, and future-ready pharma?
G
|
